- Oops!Something went wrong.Please try again later.
The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.
Celcuity remains on track to obtain feedback from the FDA to finalize the design and protocol of its Phase 3 trial in Q1 of 2022. Site identification and feasibility activities for the Phase 3 clinical trial are ongoing.
CYNK-101 is being developed in combination with standard chemotherapy, trastuzumab, and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction adenocarcinoma.
Price Action: ATRS shares are down 2.38% at $3.49, CELU stock is down 7.00% at $3.85, CELC shares are up 4.51% at $12.05 during the market session on the last check Tuesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.